FDA Critical Path Opportunities for Generic Drugs
Critical Path Opportunities for Generic Drugs , Office of Generic Drugs, Office of Pharmaceutical Science, Center for Drug Evaluation and Research – May 1, 2007. “FDAs recent critical path initiative has focused on the challenges involved in the development of new innovator drugs, devices, and biologics. Some of the focus areas identified, such as manufacturing …